Lung cancer prevalence in New South Wales (Australia): Analysis of past trends and projection of future estimates

Yu, Xue Qin; Kahn, Clare; Luo, Qingwei; Sitas, Freddy; O’Connell, Dianne

doi:10.1016/j.canep.2015.05.007

Cited by 9 publications

(6 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Total prevalence proportions (per 100,000) were calculated for each area of Eastern Morocco by dividing prevalence counts by the corresponding population size and multiplying by 100,000 [ 16 ]. Five-year prevalence was estimated by counting the number of cases diagnosed in the previous five years and still alive at a given index date [ 11 ]. For example, five-year prevalence for 2012 was estimated by counting the number of cases diagnosed between 2008 and 2012 who were still alive at the end of 2012 [ 11 ].…”

Section: Methodsmentioning

confidence: 99%

“…Five-year prevalence was estimated by counting the number of cases diagnosed in the previous five years and still alive at a given index date [ 11 ]. For example, five-year prevalence for 2012 was estimated by counting the number of cases diagnosed between 2008 and 2012 who were still alive at the end of 2012 [ 11 ]. We calculated five-year prevalence at three time points for which data were available (2010, 2011, and 2012).The proportions were expressed per 100,000 person [ 17 ].…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Exploring Geographic Variability in Cancer Prevalence in Eastern Morocco: A Retrospective Study over Eight Years

Errahhali¹,

Errahhali²,

Abda³

et al. 2016

PLoS ONE

View full text Add to dashboard Cite

BackgroundMalignant diseases have been believed to be more common in some areas of Eastern Morocco, but until now, cancer patterns have not been reported for this region. In this paper we present for the first time the cancer prevalence analysis in Eastern Morocco.MethodsCross-sectional study carried out among all patients diagnosed and/or treated with cancer at the Hassan II Regional Oncology Center (ROC) since it was established in October 2005 until December 2012. The ROC is the only hospital specialized in cancer care in Eastern Morocco.ResultsA total of 8,508 cases of cancer were registered among residents in Eastern Morocco, with a female to male ratio of 2.1. The mean age at diagnosis was 53.9 ± 15.2 years (median age = 53 years). Thus, unlike in Western countries, cancer in Eastern Morocco afflicts younger population. The areas of Eastern Morocco did not differ significantly by mean age at diagnosis (p = 0.061). However, these regions differed significantly by sex ratio (p < 0.001). The highest sex ratio was observed in Figuig, with a female to male ratio of 3.1 (75.4% of the registered case were females), followed respectively by Taourirt, Oujda-Angad, Berkane, Nador-Driouch and Jerada. Clear variation in the distribution of cancer types between areas of Eastern Morocco was observed, both in males and females (p < 0.001). Furthermore, the areas of Eastern Morocco differed significantly by cancer prevalence (p < 0.001). The highest age-standardized five-year prevalence proportion was observed in Oujda-Angad with 420.2 per 100,000, followed respectively by Berkane (311.4), Jerada (287.8), Taourirt (269.3), Nador-Driouch (213.6) and Figuig (194.4). Trends in the five-year prevalence proportions decreased in Oujda-Angad, Berkane and Jerada throughout the study period, while an increasing trend was observed in Nador-Driouch, Taourirt and Figuig.ConclusionsFor the first time, our study presents the pattern and distribution of diagnosed cancers in Eastern Morocco. Our study illustrates substantial differences in cancer patterns between areas of Eastern Morocco. These findings are important for cancer control and highlight the need to develop program aiming at controlling and preventing the spread of major cancer sites in Eastern Morocco, particularly in areas with increased cancer prevalence rates.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Exploring Geographic Variability in Cancer Prevalence in Eastern Morocco: A Retrospective Study over Eight Years

Errahhali¹,

Errahhali²,

Abda³

et al. 2016

PLoS ONE

View full text Add to dashboard Cite

show abstract

“…For example, the 5-year prevalence in 2019 was obtained by summing the number of patients with childhood cancer diagnosed between 2015 and 2019 who were alive on December 31, 2019. 11,18 We calculated the average annual percent change to summarize the changing trend. 19 The relative survival rate was calculated using the cohort survival table by the Ederer II method.…”

Section: Discussionmentioning

confidence: 99%

“…1,050 (20) 380 (24) 109 (19) 189 (19) 102 (19) 54 (23) 36 (19) 48 (39) 14 (8) 39 (15) 66 ( 14) 18 (15) 9 (11) 1,956 (37) 630 (40) 196 (35) 344 (35) 279 ( 53) 77 (31) 60 (31) 41 (33) 59 (32) 85 (34) 149 (32) 36 (31) 25 (32) 1,100 (21) 312 (20) 128 (23) 182 (18) 103 (20) 50 (21) 54 (28) 18 (15) 48 (26) 54 (21) 106 (23) 28 ( 24) 20 (25) 1,146 (22) 237 (15) 131 (23) 281 (28) 44 (8) 56 (24) 42 (22) 16 (13) 63 (34) 75 (30) 142 ( 30 Only the first primary cancer was counted for patients with multiple pri...…”

Section: Discussionmentioning

confidence: 99%

Prevalence of survivors of childhood cancer based on a population‐based cancer registry in Osaka, Japan

Kudo,

Nakata,

Morishima

et al. 2024

Intl Journal of Cancer

View full text Add to dashboard Cite

Although the survival rate of patients with childhood cancer has greatly improved, long‐term survivors face specific problems such as the late effects of cancer treatment. In this study, we estimated the number of people who had experienced childhood cancer to predict their needs for medical care and social resources. Using data from the population‐based Osaka Cancer Registry, we identified children aged 0–14 years who were diagnosed with cancer between 1975 and 2019. We estimated the prevalence on December 31, 2019, and the 5‐ and 10‐year prevalence (i.e., the number of survivors living up to 5 or 10 years after the diagnosis of cancer) over time. The prevalence proportion was age‐standardized using a direct standardization method. The prevalence estimates for Osaka were applied to the national population to determine the national prevalence in Japan. Among 8186 patients diagnosed with childhood cancer in Osaka, 5252 (987 per million) survived until December 31, 2019. The 5‐year prevalence per million increased from 194 in 1979 to 417 in 2019 (+116%), while the 10‐year prevalence increased from 391 in 1984 to 715 in 2019 (+83%). Based on the long‐term registry data, an estimated 73,182 childhood cancer survivors were living in Japan by the end of 2019. The increasing 5‐year and 10‐year prevalence proportions indicate the continued need for cancer survivorship support for children, adolescents, and young adults. These estimates of the prevalence of childhood cancer survivors, including long‐term survivors, may be useful for policymakers and clinicians to plan and evaluate survivorship care.

show abstract

“…4 There is a belief that the LC prevalence will be approximately the same in the representatives of different sex in some regions of the globe in the near future. 5 Sexual dimorphism of the LC course is observed alongside with the number of sick women increase,6,7 the female sex is an unfavorable risk factor,8 while the male sex is a prognosis negative predictive factor for the frequency and severity of the skeleton metastasis.9 However, according to YF He et al,10 MF Oliveira et al, 11 there are no gender specific features of the so-called "bone" form of LC. In recent years there has been a redistribution of the LC frequency in groups of different sexes according to the histological variants of the disease.6,12 And if among all LC patients 5-year survival is about 10% now, then in women group this figure is significantly worse.…”

Section: Introductionmentioning

confidence: 99%

Peculiarities of lung cancer clinical course in woman comparing with men

Syniachenko¹,

Yehudіna²,

Ханюков³

et al. 2018

MOJWH

View full text Add to dashboard Cite

Introduction: In recent years there has been a redistribution of the lung cancer (LC) frequency in groups of different sexes according to the histological variants, localization of the disease and dissemination. Aim: to evaluate the sexual dimorphism of the lung cancer (LC) clinical course, to reveal peculiarities of lung cancer clinical course in woman comparing with men. Patients and methods: there were 1071 LC patients under observation at the National Cancer Institute (Kyiv) from 2000 to 2015, which were included in the main object of the study. Among these patients there were 887 (82.8%) men and 184 (17.2%) women, at the age of 59.7±0.32 years and 57.0±0.89 years, respectively. Results: The patients' sex has an effect on the integral parameters of the LC course, the localization of the tumor process and the nature of the complications. The side of the lung lesions, localization in lobes, the form of the disease, the histological variant of LC and its staging, the development of small cell cancer, adenocarcinoma and squamous cell carcinoma depend on the sex of the patients. Women had more often middle lobe right lung lesion and upper lobe localization of both lungs. Women were 52% more likely to have IV lung cancer stage; the germination of LC in the ribs was not observed in women at all, and the compression syndrome and tracheal injury accordingly appeared less often at 52% and 72%, whereas pleurisy was observed 2.2 times more often. Metastasis in women was observed 27 times more often in the thyroid gland, 16.5 times-in the abdominal wall, 2.2 times-in the brain. The metastatic lesion of the skeleton (the so-called "bone form of the LC") was the prerogative of women. Adenocarcinoma of the upper lobe diagnosed in women 2.2 times more often, and squamous cell carcinoma-2 times less often. Female sex has an effect on metastases in the mediastinal and inguinal lymphatic nodes, lung, thyroid and spine. The gender parameters of survival in men and women were the same. Conclusions: the course of the LC in woman has its own dimorphism, which is a risk factor for a severe tumorous process.

show abstract

Lung cancer prevalence in New South Wales (Australia): Analysis of past trends and projection of future estimates

Cited by 9 publications

References 23 publications

Exploring Geographic Variability in Cancer Prevalence in Eastern Morocco: A Retrospective Study over Eight Years

Exploring Geographic Variability in Cancer Prevalence in Eastern Morocco: A Retrospective Study over Eight Years

Prevalence of survivors of childhood cancer based on a population‐based cancer registry in Osaka, Japan

Peculiarities of lung cancer clinical course in woman comparing with men

Contact Info

Product

Resources

About